GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Cash & Equivalents data on file, last reported at $235.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 21.69% year-over-year to $235.7 million; the trailing twelve-month figure through Mar 2026 stood at $235.7 million (down 21.69% YoY), and the FY2025 full-year result was $261.8 million, down 41.6% from the prior year.
• Cash & Equivalents retreated to $235.7 million in Q1 2026, from $261.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $845.4 million in Q1 2022 to a low of $235.7 million in Q1 2026.
• A 5-year average of $549.2 million and a median of $533.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents climbed 9.07% in 2023 and sank 46.69% in 2024, its largest moves.
• Tracing GDRX's Cash & Equivalents over 5 years: stood at $757.2 million in 2022, then fell by 11.21% to $672.3 million in 2023, then sank by 33.31% to $448.3 million in 2024, then plunged by 41.6% to $261.8 million in 2025, then slipped by 9.97% to $235.7 million in 2026.
• Business Quant data shows GDRX's Cash & Equivalents at $235.7 million in Q1 2026, $261.8 million in Q4 2025, and $273.5 million in Q3 2025.